Stockwinners Market Radar for July 01, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:55 EDT Four Corners Property Trust acquires WellNow property, T-Mobile property for $4M - Four Corners Property Trust announced the acquisition of a WellNow property and a T-Mobile property for $4M. The properties are located in a strong retail corridor in New York and are occupied under long-term net leases. The transaction was priced at a cap rate in range with previous FCPT transactions.

17:36 EDT RTX awarded $5.5B Air Force contract modification - Raytheon has been awarded a $5.5B modification to a previously awarded contract for the F117 Engine Sustainment Support contract. The modification brings the total cumulative face value of the contract to $8.24B from $2.74B. Work will be performed in San Francisco, California; Columbus, Georgia; and Tinker Air Force Base, Oklahoma, and is expected to be completed by September 30, 2027. This contract involves Foreign Military Sales to the United Kingdom, Canada, Australia, United Arab Emirates, Qatar, India, and Kuwait. No funds are being obligated at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:17 EDT Citi announces Stress Capital Buffer of 4.3%, to raise dividend to 53c from 51c - Citi announced that it has completed the Federal Reserve's 2023 Comprehensive Capital Analysis and Review stress test process. The Firm's indicative Stress Capital Buffer requirement is 4.3%, up from the current 4.0%, and the Firm's preliminary Standardized Common Equity Tier 1 capital ratio regulatory requirement is 12.3%, up from the current 12.0%, effective October 1, 2023. As of March 31, 2023, Citi's Standardized CET1 capital ratio, which includes a 100-basis-point management buffer, stood at 13.44%, above the new regulatory requirement. The Federal Reserve will provide the Firm with its final SCB requirement by August 31, 2023, and that requirement will become effective on October 1, 2023, and will remain in effect until September 30, 2024. Citi's Board of Directors approved a plan to increase the current quarterly common stock dividend of 51c to 53c per share for the third quarter of 2023. The Firm's quarterly common stock dividends are subject to approval by the Board of Directors at the customary times that those dividends are declared.

17:12 EDT Goldman Sachs to raise quarterly dividend 10% to $2.75 from $2.50 per share

17:03 EDT First Capital announces Michael Frederick succeeds William Harrod as CEO - First Capital announced that William Harrod has retired from his role as president and CEO of the company. Effective July 1, Michael Frederick will assume the role of president and CEO of the company. Frederick currently serves as the president and CEO of the bank, previously served as the CFO of the bank and the company, and has been affiliated with the Bank since 1990.

16:47 EDT Astrotech board rejects unsolicited acquisition proposal from BML Investment - Astrotech announced that its board of directors has unanimously rejected the unsolicited acquisition proposal from BML Investment Partners, received on June 26, to acquire all of the outstanding shares of common stock of the company for $17.25 per share in cash. After a thorough review, in consultation with management and its legal advisors, the board unanimously determined to reject the proposal because it is not in the best interest of the company's stockholders for the following reasons:. "The Proposal is Opportunistic and Significantly Undervalues the Company. The Board believes that the Proposal significantly undervalues the Company and prioritizes the short-term gain of BML at the expense of the Company's stockholders. The Board believes the Proposal is an opportunistic attempt by BML to purchase the Company's shares at a discounted price that significantly undervalues the Company's business. The offer price of $17.25 per share represents a significant 34% discount to the per share value of the Company's cash and short term investments as of March 31, 2023. The cash and short-term investments represent the Company's primary liquidity source for funding the development of its products and execution of its long-term business strategy. The offer price represents a more than $10 million discount to cash for which BML is expecting to benefit to the detriment and disregard of our shareholders. The offer price represents an even greater discount when considering the value of the Company's key mass spectrometry technology that is the foundation of our current and future products, and therefore does not reflect the Company's true intrinsic value or prospects. The Company has continued to drive stockholder value by expanding its offerings in existing and new markets to capitalize on opportunities for new business." The Board believes that the Company's stockholders will best be served by the Company continuing to pursue its long-term business strategy because the Board believes that the long-term value of the Company is greater than the short-term liquidation or sale value represented by the Proposal. As a result, the Proposal would deny the Company's stockholders the full benefits of the Company's developing business opportunities in bringing products to market and its overall growth strategy. For example, the Proposal does not take into account the successful results of the AgLAB Maximum Value Process(TM) method (AgLAB subsidiary) or the recent purchase order for 17 TRACER 1000 systems (1st Detect subsidiary). The partnership with Cleveland Clinic to develop the BreathTest-1000TM (BreathTech subsidiary) is another project that has the potential to create long-term value. The Board believes that BML's aim is to realize a short-term gain at the expense of the Company's other stockholders. The Board believes that BML's strategy of potentially liquidating the Company, as stated in BML's Schedule 13D, would result in unfair profits to BML at the expense of all other stockholders because the offer price of $17.25 per share is significantly less than the per share value of the Company's cash and short-term equivalents. Consistent with its history involving other public companies, the Board believes BML is targeting Astrotech for liquidation because the market value of Astrotech's common stock is less than the book value of its cash and short-term investments. If BML were to acquire the Company at $17.25 per share (excluding shares directly held by BML), BML would expend an aggregate $25 million for the remaining 87% of Company shares that it does not own, and BML would then own 100% of a Company with a value of $26.17 per share, based solely on the book value of the cash and short-term investments as of March 31, 2023. If BML were then to liquidate the Company shortly thereafter, BML would realize a gain on all of its shares that would represent a significant premium over what all other stockholders would receive based on the Proposal, to the sole benefit of BML. The Proposal states that BML has funds "readily available" to close a transaction but provides no details or evidence of any financing commitments, sources, methods, discussions or other customary disclosure regarding how BML plans to fund over $25 million in cash consideration.The Company's Board is committed to delivering long-term value to stockholders by executing on its strategic business plans and growing the Company's mass spectrometry technology and business lines. The Board will continue to work on behalf of stockholders to grow Astrotech's business and generate increasing value for its stockholders generally over the limited opportunistic interests of the few."

16:41 EDT Capital One announces Stress Capital Buffer Requirement of 4.8% - Capital One Financial announced its preliminary Stress Capital Buffer Requirement, as calculated based on the Federal Reserve's 2023 Comprehensive Capital Analysis and Review process, is 4.8%, effective October 1, 2023. Capital One's previously disclosed SCB of 3.1%, as calculated based on the 2022 CCAR process, will remain in effect through the end of the third quarter of 2023.

16:35 EDT BNY Mellon intends to raise quarterly dividend 14% to 42c per share - BNY Mellon announced its intention to increase its quarterly cash dividend on its common shares by 14% from 37c to 42c per share, commencing as early as the third quarter of 2023, subject to approval by the company's Board of Directors. On June 28, 2023, the Federal Reserve released the results of its 2023 bank stress test, which demonstrate the resilience and strength of BNY Mellon's business model and capital position. The Federal Reserve also notified the company that its preliminary Stress Capital Buffer requirement will remain 2.5%, equal to the regulatory floor. This SCB is expected to be effective from October 1, 2023 to September 30, 2024. "The results of the Federal Reserve's 2023 bank stress test once again highlight BNY Mellon's capacity to withstand extreme stress scenarios," said Robin Vince, President and Chief Executive Officer of BNY Mellon. "Combined with the power and stability of our platforms and demonstrated ability to help clients navigate uncertain markets, resiliency is a commercial attribute and a key differentiator for us. This resiliency also positions us to deliver value for our shareholders, and so we are pleased to announce the company's intention to increase our common dividend while remaining committed to maintaining strong capital ratios."

16:34 EDT Truist Financial says Fed determines stress capital buffer requirement is 2.9% - Truist Financial announced the Federal Reserve Board has determined the company's preliminary stress capital buffer requirement is 2.9%. The Federal Reserve Board will provide the company's final SCB requirement on or before Aug. 31, 2023. Once finalized, the new SCB requirement will be in effect from Oct. 1, 2023 to Sept. 30, 2024. Truist also announced plans to maintain its current quarterly common stock dividend of 52c per share, subject to approval by its board of directors.

16:32 EDT MariaDB receives NYSE continued listing standards notice - MariaDB announced that it was notified on June 28, 2023 by the New York Stock Exchange that the company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's ordinary shares was less than $1.00 per share over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of MariaDB's ordinary shares from the NYSE. The company intends to notify the NYSE of its intent to regain compliance with the applicable NYSE continued listing standards. The company can regain compliance at any time within a six-month cure period following its receipt of the NYSE notice if, on the last trading day of any calendar month during the cure period, MariaDB's ordinary shares had a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of the applicable calendar month. MariaDB's ordinary shares will continue to be listed and will continue to trade on the NYSE during the cure period, subject to the company's compliance with other NYSE continued listing standards.

16:21 EDT Walmart EVP Furner sells 4,375 common shares - In a regulatory filing, Walmart executive VP John Furner disclosed the sale of 4,375 common shares of the company on June 28 at a price of $154.73 per share.

16:15 EDT Nokia, Apple sign long-term patent license agreement - Nokia (NOK) announced it has signed a new patent cross-license agreement with Apple (AAPL) which will replace the current license that is due to expire at the end of 2023. The terms of the agreement remain confidential between the parties. Jenni Lukander, President of Nokia Technologies, said: "We are delighted to have concluded a long-term patent license agreement with Apple on an amicable basis. The agreement reflects the strength of Nokia's patent portfolio, decades-long investments in R&D, and contributions to cellular standards and other technologies." Nokia expects to recognize the revenue related to this new patent license agreement starting in January 2024. The agreement is consistent with the assumptions Nokia has disclosed in the commentary with respect to Nokia Technologies long-term outlook in its Financial Report for Q1 issued on April 20, 2023.

16:07 EDT RPC, Inc. acquires Spinnaker Oilwell Services for $79.5M - RPC, Inc. announced the acquisition, effective July 1, of Spinnaker Oilwell Services. Spinnaker, headquartered in Oklahoma City, Oklahoma, operates two facilities located in El Reno, Oklahoma and Hobbs, New Mexico and maintains 18 full-service cementing spreads. The purchase price was $79.5M in exchange for 100% of Spinnaker's equity. The transaction consideration consisted of approximately $77M of cash, and the $2M payoff and $0.5M assumption of capital lease liabilities. The agreement contains a post-closing adjustment window for an agreed-upon level of Spinnaker's working capital, as well as other usual and customary items.

16:06 EDT Tattooed Chef intends to file for voluntary Chapter 11 bankruptcy protection - Tattooed Chef announced that it intends to file for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Central District of California and intends to pursue a sale of substantially all of its assets under Section 363 of the Bankruptcy Code. In accordance with the sale process under Section 363 of the Bankruptcy Code, the Company will market its assets and solicit competing bids from interested parties. The bidding process is designed to achieve the highest and best price for the Company's assets. The Company will manage the bidding process and evaluate any bids received, in consultation with its advisors and as overseen by the Bankruptcy Court. The Company seeks to complete an expedited sale process, with any sales subject to review by creditors and approval by the Bankruptcy Court. The Company has retained SC&H Capital, an affiliate of SC&H Group, Inc, as its investment bank to manage the sale process and seek qualified bidders for its assets. The Company expects to continue operations during the Chapter 11 process, including, but not limited to, paying employees and continuing existing benefits programs, meeting commitments to customers and fulfilling go-forward obligations, including key vendor payments.

16:02 EDT Glen Burnie CEO Long to retire by end of 2023 - Glen Burnie Bancorp announced that President and CEO, John D. Long, plans to retire from the Bank by the end of 2023 to spend more time with family and pursue other opportunities. Long will work closely with the Board of Directors to ensure a smooth leadership transition and will remain at the Bank during the transition period. "On behalf of the Board of Directors, the management team, and our employees, I would like to extend our sincere gratitude to Mr. Long for his service to The Bank of Glen Burnie and Glen Burnie Bancorp," said John E. Demyan, Chairman of the Board. "During his leadership, we made great strides to modernize our technology and expand our retail and business product offerings. We are grateful for these contributions, and we wish him the best in his future endeavors. We have an experienced leadership team in place and are poised for success during this transition period and well into the future." The Board of Directors has commenced an executive search and will oversee the process of choosing Mr. Long's successor.

16:00 EDT PrimeEnergy joins the Russell 2000 Index - PrimeEnergy Resources announced that the Company was added to the broad-market Russell 2000 Index at the conclusion of the 2023 Russell Indexes annual reconstitution, effective at the US market opening on June 26, 2023. "We are pleased to have earned our inclusion in the Russell 2000 Index, one of the most widely cited performance benchmarks for U.S. small-cap companies," said Beverly Cummings, Vice President and CFO of PrimeEnergy. "This is an important event for PrimeEnergy as we continue to execute the development of our acreage position in the Permian Basin and Oklahoma."

14:39 EDT Risk Strategies acquires First Insurance from Premier Financial, no terms - Risk Strategies and Premier Financial Corporation announced that Risk Strategies has acquired Ohio-based First Insurance Group from Premier Financial Corp., a community banking and financial services holding company based in Defiance, Ohio. Founded in 1946, First Insurance Group today is one of the largest multiline agencies in the state of Ohio. With deep technical skills, broad industry experience and product lines and value-added services the agency offers custom insurance placement services for commercial and personal property and casualty, health, life, and employee benefits, as well as fee-based consulting services for employee benefits programs and a variety of related services. "We're excited to bring the First Insurance Group team into the Risk Strategies family," said Steve Giannone, Risk Strategies Central Region Leader. "We see a great cultural and business fit between our organizations, including a similar commitment to strong community support and caring, that will fuel continued success across Ohio."

13:35 EDT Zealand Pharma submits NDA for dasiglucagon in congenital hyperinsulinism - Zealand Pharma announced the submission of a New Drug Application to the US Food and Drug Administration for dasiglucagon for the prevention and treatment of low blood sugar in pediatric patients 7 days of age or older with congenital hyperinsulinism. The submission is based on the results from two pivotal Phase 3 trials and interim results from an ongoing long-term extension trial.

13:02 EDT Baker Hughes reports U.S. rig count down 8 to 674 rigs - Baker Hughes reports the U.S. rig count is down 8 from last week to 674, with oil rigs down 1 to 545, gas rigs down 6 to 124 and miscellaneous rigs down 1 to 5. The U.S. rig count is down 76 rigs from last year's count of 750, with oil rigs down 50, gas rigs down 29 and miscellaneous up 3. The U.S. offshore rig count is unchanged at 19, up 2 year-over-year.

13:01 EDT Baker Hughes reports U.S. rig count down 8 to 674 rigs

12:33 EDT Teva announces data from PEARL study on AJOVY in migraine prevention - Teva Pharmaceutical announces further data from the pan-European PEARL study investigating the impact of AJOVY on the prevention of migraine in a real-world setting, due to be completed in 2024. The data from the 3rd interim analysis reveals that almost 60% of patients achieved a greater than or equal to50% reduction in monthly migraine days from baseline for migraine prevention, with sustained improvement in disability scores and acute medication use observed over 12 months. Treatment persistence rates were high, with 82.3% of patients remaining on treatment by month 12. Not only was fremanezumab effective in preventing migraine attacks in patients with chronic and episodic migraine, but it has also shown to be effective in reducing the severity and duration of remaining migraine attacks. Four abstracts from the third interim analysis of the PEARL study will be presented at the 9th European Academy of Neurology Congress in Budapest, Hungary. The primary analysis is being presented as an oral presentation by Professor Cristina Tassorelli, Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy on July 1, 2023.

12:17 EDT Acadia Healthcare forms New Hampshire JV with SolutionHealth - Acadia Healthcare announced that it has formed a joint venture with SolutionHealth to build a 144-bed behavioral health hospital in southeast New Hampshire. "This partnership expands Acadia's acute service line into a new state with a premier health system. The hospital will offer a full continuum of inpatient behavioral healthcare services for patients, including the most vulnerable members of the community. This project will be supported by the $15M in state funding from the New Hampshire Department of Health and Human Services to defray capital costs for the construction of the new hospital. The new hospital represents the 19th joint venture partnership for Acadia. Joint ventures continue to be a key strategic growth lever for the company," Acadia stated.

12:00 EDT Virgin Galactic falls -7.8% - Virgin Galactic is down -7.8%, or -33c to $3.90.

12:00 EDT Transocean rises 9.2% - Transocean is up 9.2%, or 59c to $7.01.

12:00 EDT Offerpad Solutions rises 16.7% - Offerpad Solutions is up 16.7%, or $1.92 to $13.45.

11:53 EDT Genentech announces four-year follow-up data for Evrysdi in SMA - Genentech announced long-term data for Evrysdi from the open-label extension of the pivotal FIREFISH study, reinforcing its sustained efficacy and safety profile in children with Type 1 spinal muscular atrophy. FIREFISH is a two-part study in babies aged 1-7 months at the time of enrollment. After four years of treatment with Evrysdi, many of the babies, now young children, continued to improve their ability to sit, stand and walk without support. All the Evrysdi-treated children who were alive at the time of the primary analysis were still alive at month 48. Additionally, the majority of infants maintained their ability to feed by mouth and swallow up to month 48. Motor function was assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition and Hammersmith Infant Neurological Examination 2 and abilities were either maintained or improved over four years of Evrysdi treatment. Without treatment, children with Type 1 SMA are not expected to live past two years of age and are never able to sit without support. These data were presented at the Cure SMA Research & Clinical Care Meeting, June 28 - 30, 2023. Among the infants treated with Evrysdi, 37 were able to sit without support for at least 5 seconds at month 48, compared to 35 at month 24. In addition, 36 infants were able to sit without support for at least 30 seconds at month 48, up from 23 infants at month 24. Between month 24 and month 48, three infants gained the ability to stand alone and one infant gained the ability to walk alone. Evrysdi is the first and only small molecule pre-mRNA splicing modifier that targets survival motor neuron-2 for the treatment of SMA, and can be administered at home in liquid form by mouth or by feeding tube. No treatment-related adverse events led to treatment discontinuation or withdrawal from the study, and the rate of AEs decreased by 71% between the first and fourth 12 month periods. The most common AEs were pyrexia, upper respiratory tract infection and pneumonia. The rate of hospitalizations decreased over the study period. Genentech leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.

11:15 EDT General Motors acquires battery software startup ALGOLiON - General Motors announced that it has acquired substantially all the assets of Israel-based battery software startup ALGOLiON Ltd. for an undisclosed sum. "The acquisition was led by the newly formed Technology Acceleration and Commercialization organization, a group within GM that works to identify emerging technology that can support GM's leadership position in battery development through investments, acquisitions or partnerships," GM stated. "ALGOLiON has developed cutting edge battery analytics and prediction software that will help General Motors deliver great performing EVs for our customers," added Gil Golan, vice president, TAC.

11:04 EDT Scholar Rock announces data from Phase 2 TOPAZ trial extension period - Scholar Rock announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab. These data showed that continued treatment with apitegromab over the extended treatment period was associated with substantial and sustained improvement in motor function, as well as improvements in patient-reported outcome measures in patients with nonambulatory Types 2 and 3 spinal muscular atrophy receiving survival motor neuron-targeted therapy. Detailed results were presented today by Thomas Crawford, M.D., of Johns Hopkins Medicine, and the lead principal investigator of the TOPAZ trial, during two podium presentations at the Cure SMA Research & Clinical Care Meeting in Orlando, Florida. Substantial and Sustained Gains in Motor Function Observed Over the Extended Treatment Period: Nonambulatory patients experienced substantial and sustained gains in Hammersmith Functional Motor Scale-Expanded and Revised Upper Limb Module scores over the 36-month extended treatment period from baseline. For the 36-month data, an observed case analysis was conducted, which pooled data for all nonambulatory patients and was based upon the available data. These analyses exclude data for patients post scoliosis surgery. Improvement in Patient-Reported Outcomes Consistent with Improvements in Motor Function: Nonambulatory patients had improvements in PEDI-CAT and PROMIS-Fatigue that were consistent and sustained at 36 months. The mean change in PEDI-CAT daily activity domain from baseline at 36 months was 2.2, indicating an improvement in the ability to perform daily activities. The mean change in PROMIS-Fatigue from baseline at 36 months was -4.6, indicating a decline in fatigue. These improvements in PEDI-CAT and PROMIS-Fatigue were generally consistent with improvements in motor function across the 36 months of the study period. Consistent Safety Data: Treatment-emergent adverse events at 36 months were consistent with previous reports at 12 and 24 months, with no new findings after an aggregate of 198 patient-years of exposure. TEAEs were mostly mild-to-moderate in severity, and generally consistent with the underlying patient population and background therapy. The five most common TEAEs were headache, pyrexia, COVID-19, nasopharyngitis, and upper respiratory tract infection. No deaths or suspected unexpected serious adverse reactions or hypersensitivity reactions were observed with apitegromab at 36 months. A total of 21 serious TEAEs were reported over the 36-month treatment period. No patients displayed positive titers for apitegromab antibodies. More than 90 percent of nonambulatory patients remained on treatment in the extension study.

10:41 EDT SoFi rallies 6% to $9.22 after Supreme Court rejects Biden student loan program

10:40 EDT SoFi Technologies trading resumes

10:38 EDT Supreme Court rejects first two challenges Biden's student loan plan - The Supreme Court rejected the first of two challenges to President Biden's plan to relieve student loan debt. The court said two borrowers didn't have legal standing to challenge the program. Companies that may be impacted by new student loan regulations include Navient (NAVI), SoFi Technologies (SOFI), Nelnet (NNI) and SLM (SLM).

10:29 EDT Freedom Holding drops 1% to $82.50 following Citron tweet

10:14 EDT Textron announces order for 40 Cessna Skyhawks to support pilot training - Textron Aviation announced an agreement with ATP Flight School for the purchase of 40 Cessna Skyhawk aircraft to be delivered in 2025. The piston aircraft will add to ATP's existing fleet of nearly 200 Skyhawks, positioned across 82 training centers nationwide. This is the second fleet purchase of Cessna Skyhawks for ATP's Airline Career Pilot Program in less than a year, as the flight school scales to train 20,000 airline pilots by 2030. In October 2022, ATP and Textron Aviation agreed to the purchase of 55 Cessna Skyhawks, with deliveries starting in the third quarter of 2023.

10:00 EDT Gatos Silver falls -4.8% - Gatos Silver is down -4.8%, or -19c to $3.77.

10:00 EDT XPeng rises 7.7% - XPeng is up 7.7%, or 91c to $12.74.

10:00 EDT Bausch + Lomb rises 9.5% - Bausch + Lomb is up 9.5%, or $1.83 to $21.01.

09:48 EDT Addentax Group Corp trading resumes

09:47 EDT Core Laboratories falls -5.4% - Core Laboratories is down -5.4%, or -$1.32 to $23.03.

09:47 EDT Bausch + Lomb rises 7.6% - Bausch + Lomb is up 7.6%, or $1.47 to $20.64.

09:47 EDT Bright Health rises 13.2% - Bright Health is up 13.2%, or $1.44 to $12.36.

09:41 EDT MicroStrategy shares, bitcoin price fall after WSJ report on ETF filings

09:31 EDT Capricor Therapeutics announces 24-month results from HOPE-2 study - Capricor Therapeutics announced 24-month safety and efficacy results from its ongoing HOPE-2 open label extension study with its lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy. Data from the OLE study demonstrated that the majority of patients had an improvement in left ventricular ejection fraction, after two years of CAP-1002 treatment, which suggests preservation of cardiac function. Additionally, patients continue to show statistically significant benefit after two years of treatment in the Performance of the Upper Limb scale when compared to the original rate of decline of the placebo group from HOPE-2 after one year. Furthermore, the OLE study continues to show a favorable safety profile for long-term treatment of CAP-1002. These data will be featured in an oral presentation being webcast today at this year's Parent Project Muscular Dystrophy Annual Conference. The HOPE-2-OLE study previously met its primary endpoint at the one-year timepoint on the PUL v2.0 scale. At the 24-month timepoint, data showed statistically significant differences in the PUL v2.0 in the OLE treatment group when compared to the original rate of decline of the placebo group from HOPE-2 after one-year. LVEF was measured using cardiac magnetic resonance imaging and six of nine patients showed improvements in heart function with CAP-1002 treatment compared to their final assessment at the end of the HOPE-2 study. Over time, there was an increasing correlation with PUL v2.0 and ejection fraction results. CAP-1002 treatment during the HOPE-2-OLE study continues to yield a consistent safety profile and has been well-tolerated throughout the study. The HOPE-2-OLE study remains ongoing, and participants continue to be monitored for safety and functional performance.

09:28 EDT Zai Lab, Argenx announce approval of VYVGART in China - Zai Lab announced that China's National Medical Products Administration has approved the Biologics License Application for VYVGART a first-in-class neonatal Fc receptor antagonist, as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive. Zai Lab will now work with the National Healthcare Security Administration for NRDL inclusion to enable broad access for patients.

09:18 EDT Sagaliam announces amendment to non-binding term sheet with Enzolytics - Sagaliam Acquisition amended the executed non-binding term sheet for the purchase of Biogenysis and Virogentics, operating subsidiaries of Enzolytics amending the combined purchase price to $450,000,000. Sagaliam expects to raise additional capital through a private investment in public equities transaction. The anticipated capital raise from the PIPE is expected to be used by VIRO to fund the clinical trials of its anti-HIV therapeutic ITV-1, complete the African Project and advance marketing of IPF Immune. The funds are to be used by BGEN to complete the production of and test species-specific monoclonal antibodies for treating COVID-19, HIV, and Feline Leukemia. The funding will significantly enhance BGEN's drug discovery capabilities using its proprietary, cutting-edge Artificial Intelligence technology and enlarge its IP portfolio while also expanding the AI platform's capabilities to advance health care based on reactive disease care to P4 medicine, namely care that is predictive, preventive, personalized and participatory.

09:05 EDT eXp World's eXp Realty accelerates agent rewards, reduce revenue share criteria - eXp Realty announced that for the first time, it is refining revenue share criteria for its agents. eXp Realty is reducing its current Frontline Qualifying Agent tier 7 threshold from 40 to 30 FLQA. "At a time when other companies are increasing their rev share thresholds or imposing new fees, eXp Realty is the only brokerage lowering revenue share criteria for agents, fueling exponential opportunities for them to build their legacies," said Glenn Sanford, founder and CEO of eXp Realty. "Revenue share is an important income opportunity for agents, so this change is a testament to the singular agent-centric focus we were built on. We believe in our aligned compensation model, which was created to reward agents for both production and contributions to eXp Realty's growth."

09:03 EDT Nuvei, CNBS Software partner to transform payment processing in SAP ecosystem - Nuvei announces a new commercial partnership with CNBS Software. This collaboration will enhance payment processing capabilities for businesses utilizing SAP ECC and S4 systems through seamless integration, enhanced security, and expanded payment options. CNBS Software's partnership with Nuvei enables it to offer its customers an integrated payment solution that aligns with their existing SAP environment. Nuvei's advanced payment solution, including card acquiring and ACH online bank transfers, provides a modern, robust and secure payment infrastructure for businesses utilizing SAP solutions. CNBS will also benefit from Nuvei's experience gleaned from decades of servicing ERP payment customers. Through leveraging Nuvei's enhanced payment services, CNBS is optimizing its payment workflows, ensuring efficiency and accuracy.

08:59 EDT Nikola regains Nasdaq listing compliance - In a regulatory 8-K filing last night, the company stated: "On June 29, 2023, Nikola received written notice from The Nasdaq Stock Market LLC informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1), which requires that companies listed on the Nasdaq Global Select Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from June 14, 2023 to June 28, 2023, the closing bid price of the Company's common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5450(a)(1) and that the matter was now closed."

08:35 EDT Bausch Health's Bausch + Lomb to acquire Novartis' XIIDRA - Bausch + Lomb Corporation (BLCO), a subsidiary of Bausch Health Companies (BHC), announced that it has entered into a definitive agreement with Novartis (NVS) to acquire XIIDRA 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye. Under the terms of the agreement, Bausch + Lomb, through an affiliate, has agreed to acquire XIIDRA, libvatrep and AcuStream from Novartis for up to $2.5B, including an upfront payment of $1.75B in cash with potential milestone obligations up to $750M based on sales thresholds and pipeline commercialization. Bausch + Lomb will also bring on the sales force supporting XIIDRA. Bausch + Lomb has obtained fully committed financing from J.P. Morgan for the transaction and intends to finance the $1.75B upfront cash purchase price with new debt prior to closing. The transaction is expected to close by the end of 2023 and be immediately accretive to Bausch + Lomb. The transaction was approved by the Board of Directors at each of the respective companies and is subject to receipt of regulatory approval and other customary closing conditions.

08:33 EDT Baijiayun announces inclusion in Nasdaq Global Market - Baijiayun Group announced that its Class A ordinary shares will be transferred from the Nasdaq Capital Market to the Nasdaq Global Market effective with the open of business on June 30, 2023. The shares will continue trading under its current ticker symbol "RTC." The financial and liquidity requirements for the Nasdaq Global Market are more stringent than those for the Nasdaq Capital Market.

08:31 EDT Galiano Gold awarded mining contract - Galiano Gold is pleased to announce the company has awarded a mining contract as it progresses towards the resumption of hard rock mining operations in the fourth quarter at its Asanko Gold Mine, located in the Asankrangwa gold belt in Ghana. The AGM is a 50/50 Joint Venture with Gold Fields Ltd., which is managed and operated by Galiano. All figures are stated in US dollars unless otherwise stated. The company published the details of a new life of mine plan on March 28, 2023. The report titled "NI 43-101 Technical Report and Feasibility Study for Asanko Gold Mine, Ghana" with an effective date of December 31, 2022 describes an 8.5-year mine life with a robust after-tax net present value at a 5% discount rate of $343M (using $1,700 per ounce gold). Annual gold production approximately doubles from the 2023 guidance of 100,000 - 120,000 ounces to 250,000 ounces per year from 2025.

08:20 EDT Molina to acquire Brand New Day, Central Health Plan of California for $510M - Molina Healthcare announced that it has entered into a definitive agreement to acquire 100% of the issued and outstanding capital stock of Brand New Day and Central Health Plan of California, each of which is a wholly owned subsidiary of Bright Health Company of California, or BHCA. Relevant transaction terms and features are as follows: The purchase price for the transaction is approximately $510M, net of certain tax benefits, representing 28% of expected 2023 premium revenue of $1.8B. BHCA currently offers MAPD, D-SNP, and C-SNP products in 23 counties in California, with 60% overlap with Molina's Medicaid footprint. As of March 31, 2023, BHCA served approximately 125,000 members. The transaction represents a strong strategic fit with Molina's expanded 2024 Medi-Cal contract. It accelerates Molina's D-SNP growth initiatives and activates the Los Angeles County 2024 D-SNP option the company had negotiated with the state. Today's announcement is expected to add $1.00 per share to new store embedded earnings, bringing the expected total to $5.50 per share. Molina intends to fund the purchase with available funds including cash on hand. The transaction is subject to federal and state regulatory approvals, the solvency and continued operation as a going concern of Bright Health Group throughout the pre-closing period, and other closing conditions. It is expected to close in the first quarter of 2024.

08:13 EDT Ocean Power board approves adoption of tax benefits preservation plan - Ocean Power announced that its board of directors has approved the adoption of a tax benefits preservation plan in the form of a Section 382 Rights Agreement. The plan is designed to protect and preserve OPT's tax assets primarily associated with net operating loss carryforwards or NOLs that could potentially be utilized in certain circumstances to offset OPT's future taxable income and reduce its federal income tax liability. Section 382 of the Internal Revenue Code imposes limitations on the future use of a company's NOLs if it undergoes an "ownership change." OPT's ability to benefit from its tax assets would be substantially limited by Section 382 if an "ownership change" occurred. A company experiences an "ownership change" for tax purposes if the percentage of stock owned by one or a group of its 5% stockholders increases by more than 50 percentage points over a rolling three-year period over the lowest percentage of stock of such corporation owned by such stockholders at any time during that period. In order to protect OPT's NOLs from being limited or permanently lost under Section 382, the tax benefits preservation plan is intended to reduce the likelihood of an unintended "ownership change" occurring through the buying and selling of OPT's common stock, $0.001 par value per share. OPT's tax benefits preservation plan is intended to deter any person or group from acquiring beneficial ownership of 4.99% or more of OPT's outstanding common stock without the approval of the Board. OPT's tax benefits preservation plan does not, however, block anyone from buying or selling OPT's common stock. Accordingly, there can be no assurance that the tax benefits preservation plan will prevent an "ownership change." Under the terms of the tax benefits preservation plan, OPT will distribute to its stockholders one preferred stock purchase right for each share of OPT's common stock held as of the close of business on July 11. Any shares of common stock issued after the July 11 record date will be issued together with associated preferred stock purchase rights. Under the tax benefits preservation plan, the rights will initially trade with OPT's common stock. The rights will generally become exercisable only if a person acquires beneficial ownership of 4.99% or more of OPT's outstanding common stock, without the approval of the Board, after the first public announcement by OPT of the adoption of the tax benefits preservation plan. A person or group who acquires, without the approval of the board, beneficial ownership of 4.99% or more of OPT's outstanding common stock could be subject to significant dilution. If the preferred stock purchase rights become exercisable, all holders of rights, other than the person or group triggering the rights, will be entitled to purchase OPT's common stock at a 50% discount. The board also has the option to cause the exchange of one share of common stock for each preferred stock purchase right held. Preferred stock purchase rights held by the person or group triggering the rights will become null and void and will not be exercisable, exchangeable, or transferable. Stockholders who beneficially owned 4.99% or more of OPT's outstanding common stock prior to the first public announcement by OPT of the adoption of the tax benefits preservation plan will not trigger any penalties under the tax benefits preservation plan so long as they do not acquire beneficial ownership of any additional shares of common stock at a time when they still beneficially own 4.99% or more of such common stock. The board also has the discretion to exempt any acquisition of OPT's common stock from the provisions of the tax benefits preservation plan. The preferred stock purchase rights and the tax benefits preservation plan will expire no later than June 29, 2026. The preferred stock purchase rights and the tax benefits preservation plan may also expire on an earlier date upon the occurrence of other events, including a determination by OPT's board that the tax benefits preservation plan is no longer necessary for the preservation of OPT's tax attributes. The preferred stock purchase rights may also be redeemed, exchanged, or terminated prior to their expiration.

08:10 EDT Strata Skin Sciences appoints Geiger to chairman of its board of directors - STRATA Skin Sciences announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. In his current role, Geiger serves as the founder and managing partner of Accelmed,

08:09 EDT Trxade Health, Superlatus sign definitive merger agreement - Superlatus announced that it has signed a definitive agreement to be acquired by TRxADE HEALTH, a pharmaceutical exchange platform provider. Upon closing of the Merger, shareholders of Superlatus will receive an aggregate of 173,463 shares of MEDS stock, which will be comprised of 136,436 shares of MEDS common stock, representing 19.99% of the total issued and outstanding MEDS common stock at the closing of the Merger, and 37,027 shares of a new class of MEDS non-voting convertible preferred stock with a conversion ratio of 100 to one, multiplied by such shareholder's pro rata percentage ownership. In addition, MEDS plans to divest its existing operating business and assets shortly after the Merger. Other significant closing conditions include the acquisition by Superlatus of Prestige Farms a poultry processing business, and Sapientia, a food tech business led by Dr. Eugenio Bortone. Superlatus' interim CEO, Tim Alford, commented: "We are pleased to make this announcement as the combination of these two entities will allow us to unlock each of their individual synergies and competitive advantages to successfully form a global consolidation platform for the dynamic and growing food and healthy snack market. Additionally, this powerful merger will lay the foundation for substantial market share gains and provide us with tremendous opportunities for accretive acquisitions to grow revenues, expand margins, and enhance profitability."

08:08 EDT Applied Digital announces strategic collaboration with Hewlett Packard - Applied Digital (APLD) announced a collaboration with Hewlett Packard Enterprise (HPE), a global edge-to-cloud company. As part of the collaboration, HPE will deliver its powerful, energy-efficient supercomputers that are proven to support large-scale AI through Applied Digital's AI cloud service. Applied Digital will leverage HPE Cray XD supercomputers, featuring NVIDIA H100 GPUs, to enhance its AI Cloud service and efficiently support critical workloads such as AI, machine learning, rendering, and HPC tasks involving digital modeling and simulation. "We are excited to partner with HPE to elevate our AI Cloud Service offering and further capitalize on the growth we are experiencing in AI applications and demand for our next-generation digital infrastructure," said Wes Cummins, CEO of Applied Digital. "HPE's renowned reputation and expertise in running AI at scale further solidifies our position as a trusted partner in this space. This partnership comes at a pivotal time for our company as we continue to expand our current capacity pipeline of up to 200MW for our HPC data centers."

08:06 EDT Baudax Bio acquires TeraImmune, terms not disclosed - Baudax Bio announced the acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases. Gerri Henwood, President and Chief Executive Officer of Baudax Bio, will continue as CEO of the combined entity. In conjunction with the transaction, Yong Chan Kim, Ph D, former Chief Executive Officer of TeraImmune, will be appointed to the Board of Directors of Baudax.

08:05 EDT CytomX Therapeutics announces $30M private placement from BVF Partners - CytomX Therapeutics has entered into an agreement with BVF Partners for a private placement that is expected to result in initial gross proceeds of approximately $30 million. In the private placement, CytomX is selling pre-funded warrants to purchase up to 14,423,077 shares of common stock, accompanying Tranche 1 warrants to purchase up to 5,769,231 shares of common stock and accompanying Tranche 2 warrants to purchase up to 5,769,231 shares of common stock, at a combined price of $2.08 per share of pre-funded warrant and accompanying common warrants, representing a premium of 25% to volume weighted average price over the prior 30 trading days through June 28, 2023. Each pre-funded warrant will have an exercise price of $0.00001 per share of common stock, will be exercisable immediately and will be exercisable for 20 years. The accompanying Tranche 1 common warrants will have an exercise price of $4.16 per share of common stock, will be immediately exercisable and expire on July 3, 2025 and the accompanying Tranche 2 common warrants will have an exercise price of $6.24 per share of common stock, will be immediately exercisable and expire on July 3, 2026. CytomX anticipates aggregate initial gross proceeds from the offering will be approximately $30 million, which are expected to extend the Company's cash runway into the second half of 2025, based on CytomX's current operating plan. CytomX also has the potential to receive up to an additional $60 million if all warrants are fully exercised for cash.

08:04 EDT Bausch + Lomb to acquire Xiidra, libvatrep from Novartis for $1.75B upfront - Bausch + Lomb (BLCO) announced it has entered into a definitive agreement with Novartis (NVS) under which Bausch + Lomb will acquire Xiidra 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease, or DED, focusing on inflammation associated with dry eye. The strategic acquisition of Xiidra will complement Bausch + Lomb's existing dry eye portfolio that includes eye and contact lens drops from the company's consumer brand franchises and its pharmaceutical business that features Miebo, which was recently approved by the FDA as the first and only approved eye drop for DED that directly targets tear evaporation. Xiidra and Miebo work differently to target distinct elements of the DED cycle. As part of the transaction, Bausch + Lomb will also acquire libvatrep, an investigational compound being studied for the treatment of chronic ocular surface pain, and AcuStream technology, an investigational device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.5,6 Libvatrep is currently in Phase 2b development with study results expected in the third quarter of 2023. Under the terms of the agreement, Bausch + Lomb, through an affiliate, has agreed to acquire Xiidra, libvatrep and AcuStream from Novartis for up to $2.5B, including an upfront payment of $1.75B in cash with potential milestone obligations up to $750M based on sales thresholds and pipeline commercialization. Bausch + Lomb will also bring on the sales force supporting Xiidra. Bausch + Lomb has obtained fully committed financing from J.P. Morgan for the transaction and intends to finance the $1.75B upfront cash purchase price with new debt prior to closing. The transaction was approved by the board of directors at each of the respective companies and is subject to receipt of regulatory approval and other customary closing conditions. The transaction is expected to close by the end of 2023 and will be immediately accretive. Bausch + Lomb intends to maintain its strong balance sheet and expects to return to current leverage levels within approximately 24 months of closing.

08:04 EDT Novartis to divest 'front of eye' ophthalmology assets to Bausch + Lomb - Novartis (NVS) announced that it has signed an agreement to divest "front of eye" ophthalmology assets to Bausch + Lomb (BLCO) in a transaction valued up to $2.5B, including $1.75B in upfront cash, plus additional milestone payments. The deal includes Xiidra, which Novartis calls "the first approved prescription treatment for the signs and symptoms of dry eye disease," and investigational medicine SAF312, or libvatrep, which is in development as a first-in-class therapy for chronic ocular surface pain, or COSP, as well as the rights for use of the AcuStream delivery device in dry eye indications and OJL332, a second generation TRPV1 antagonist in pre-clinical development. "This transaction will enhance our focus on prioritized innovative medicines to alleviate society's greatest disease burdens, achieve the greatest patient impact and drive our growth strategy. Our ongoing portfolio refinement enables us to best deploy our scientific expertise and resources towards priority programs and therapeutic areas, while remaining open to opportunistic development for additional high impact conditions leveraging our advanced technology platforms. We believe that Bausch + Lomb has the capabilities, scale and commitment to continue the work of Novartis in delivering and developing much needed therapies for patients suffering from dry eye and related conditions," said Ronny Gal, Chief Strategy & Growth Officer of Novartis. Under the terms of the agreement, Novartis will receive milestone payments up to $750M linked to anticipated future sales for Xiidra, SAF312 and OJL332. Novartis will continue to supply Xiidra to patients on behalf of Bausch + Lomb, via transitional agreements for a limited period post-close, to ensure consistent supply for patients. Closing is anticipated in the second half of 2023 subject to customary conditions.

08:02 EDT SeaStar Medical to sponsor Critical Care Time podcast series - SeaStar Medical Holding announces its primary sponsorship of the first season of the Critical Care Time podcast series. These 24 weekly podcasts will delve into vital medical issues facing healthcare professionals who care for critically ill patients.

07:50 EDT Metals Company welcomes polymetallic nodules assessment under NDAA - TMC the metals company welcomed the inclusion of polymetallic nodules in a report requested by the House Armed Services Committee to the Assistant Secretary of Defense for Industrial Base Policy under the National Defense Authorization Act. Entitled "H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; and H.R. 1282 - Major Richard Star Act" and submitted June 21 (published yesterday), the House Armed Services request under the NDAA includes a "roadmap recommending how the United States can have the ability to source and/or process critical minerals in innovative arenas, such as deep-sea mining, to decrease reliance on sources from foreign adversaries and bolster domestic competencies." TMC Chairman and CEO, Gerard Barron, said, "Given the known deficit of domestic supply and processing of critical lithium-ion battery cathode materials including cobalt, nickel, and manganese, the House request for the U.S. Department of Defense to explore the possibility to process polymetallic nodules in the U.S. is timely. By onshoring primary processing and refining of nodules, the U.S. could secure supply and achieve mineral independence in four important battery metals, support domestic companies and jobs, and drastically reduce the environmental and social impacts that currently plague geopolitically-complex battery material supply chains."

07:46 EDT Constellation Brands CFO says closer to net leverage ratio goal - "The solid top-line performance of our Beer Business has reaffirmed our confidence in our annual plans and objectives, and we expect our Wine and Spirits Business to accelerate toward its Fiscal 24 outlook throughout the balance of the year. We are now closer to our net leverage ratio goal while continuing to return cash to shareholders in-line with our dividend payout ratio target and advancing our modular brewery capacity expansions per capital allocation priorities," said CFO Garth Hankinson

07:40 EDT Jushi completes disclosed amendments to 12% Second Lien notes, warrants - Jushi announced that it has completed the amendments to the Company's 12% Second Lien Notes and detached warrants expiring December 7, 2026 previously disclosed in the Company's press release dated June 6, 2023. The Company entered into definitive documentation evidencing the Amendments with the trustee to amend the trust indenture and with the collateral agent to amend the warrants. The Amendments include the removal of a covenant in the trust indenture giving the right to holders of Notes to require the Company to repurchase the Notes for 105% of outstanding principal and accrued and unpaid interest upon a change of control, and a reduction of the exercise price of the Warrants for each subordinate voting share from US$2.086 to US$1.00.

07:12 EDT XPeng launches G6 Ultra Smart Coupe SUV in China - XPeng announced yesterday "the official launch of its G6 Ultra Smart Coupe SUV, the Company's inaugural model based on its next-generation technology architecture, SEPA2.0, in China. Customers will be able to experience the Company's next-generation Smart EV innovation at a price range between 209,900 RMB to 276,900 RMB, with initial deliveries to commence in July 2023 for customers in China. Equipped with XNGP, XPENG's full-scenario ADAS solution, and XPower, XPENG's 800V powertrain system and 800V high-voltage SiC platform, alongside cutting-edge front and rear integrated aluminum body die-casting and CIB battery-body integration technology, this new model represents the next generation of Smart EVs - catering to essential demand of customers by the most advanced technologies in the industry."

07:06 EDT Stratasys board rejects Nano Dimension revised partial tender offer - Stratasys (SSYS) announced that its board of directors, after consultation with its independent financial and legal advisors, unanimously determined that the revised partial tender offer by Nano Dimension (NNDM) on June 27 to acquire ordinary shares of Stratasys for $20.05 per share in cash substantially undervalues the company and is not in the best interests of Stratasys shareholders. Accordingly, the board unanimously recommends that shareholders reject the revised offer and deliver a notice of objection against the offer. On May 30, the Stratasys board rejected Nano's previous partial tender offer to acquire ordinary shares of Stratasys for $18.00 per share in cash. Stratasys urges shareholders not to tender into Nano's partial offer. Tendering into Nano's partial offer would only encourage Nano's opportunistic and coercive attempt to acquire Stratasys at an inadequate price. Unlike tender offers in the United States, under Israeli rules, Nano's tender offer will fail if the shares covered by submitted notices of objection are greater than or equal to the number of shares tendered in the offer. Therefore, in addition to not tendering, filing a notice of objection could help cause the tender to fail. Simply not tendering could result in non-tendering shareholders being left as minority shareholders in a company controlled by Nano. Therefore, we strongly urge shareholders to file their notice of objection in order to reduce the risk of becoming a minority shareholder.

07:01 EDT OTC Markets welcomes VWF Bancorp to OTCQX - OTC Markets Group announced VWF Bancorp, the holding company for Van Wert Federal Savings Bank, has qualified to trade on the OTCQX Best Market. VWF Bancorp, Inc. upgraded to OTCQX from the OTCQB Venture Market.

06:47 EDT Bright Health enters pact with Molina to sell CA Medicare Advantage for $600M - Bright Health Group (BHG) announced that it has entered into a definitive agreement with Molina Healthcare (MOH), to sell its California Medicare Advantage business, Brand New Day and Central Health Plan, for a total purchase consideration of $600M. Upon closing, the proceeds of the sale will significantly strengthen Bright Health's capital position. The company intends to use the proceeds to satisfy its obligations to its bank lenders with the remaining proceeds used towards liabilities in its discontinued ACA insurance business. Bright Health is also announcing that it has extended a waiver and amendment to its credit facility. As part of the agreement, Bright Health Group's Consumer Care Delivery business will enter into a provider agreement with Molina to serve Medicaid and ACA Marketplace populations in Florida and Texas in 2024. The transaction is subject to regulatory approval and other closing conditions. The closing of the transaction is expected to occur by early 2024 and is not subject to a financing condition. Bright Health does not intend to comment or disclose further developments until the transaction is closed.

05:23 EDT Wabtec sells 17 narrow-gauge locomotives to CBH Group, terms undisclosed - The CBH Group has entered into an agreement with Wabtec to acquire 17 narrow-gauge locomotives, marking a significant investment in expanding the co-operative's rail fleet as part of the 'Path to 2033 Strategy'.

05:12 EDT Cummins assumes full ownership of Hydrogenics - Cummins has announced the buyout of Air Liquide's 19% interest in Hydrogenics. Cummins acquired Hydrogenics in 2019, adding key fuel cell and electrolyzer technologies to its portfolio. Cummins' buyout reinforces its commitment to these technologies and the increasing importance they will play in creating value for all stakeholders and decarbonizing our world. This move enables continued investment and growth in hydrogen technologies to meet rapidly growing demand.